ANGOAngioDynamics, Inc.
$11.22+1.5% 1Y
$11.22
$9.7052 weeks$16.12
Latest close: below its 200-day averageOct 8, 2026what changed →
ANGO in its own filings
ANGO's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
428
Events found in the filings · across 1,681 filings · the record starts in 2004
- Hard flags
- 1
Hard flags
- Most recent filing
- Oct 8, 2026
Most recent filing · Form 10-Q
- Record starts
- Jul 29, 2004
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Jan 5, 2027
- Change in certifying accountant2 occurrences
- 2016-10-07
- Late periodic reporthistorical
- 2014-10-10
- SEC comment-letter activity15 occurrences
- 2024-03-22
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 8, 2026AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability.Earnings release · press release
- Oct 8, 2026On October 3, 2026, AngioDynamics, Inc. (“AngioDynamics” or the “Company”) entered into an employment agreement with Eric Honroth (the “Employment Agreement”), pursuant to which Mr. Honroth will serve as President and Chief Executive Officer of the Company.Material agreement entered · Form 8-K
- Jul 14, 2026AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability.Earnings release · press release
- Apr 23, 2026On April 23, 2026, AngioDynamics, Inc. (the “Company” or “AngioDynamics”) filed a complaint commencing a patent infringement lawsuit in the United States District Court for the District of Delaware against Endovascular Engineering, Inc. (“E2”)Other event · Form 8-K
- Apr 2, 2026AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued.Earnings release · press release
- Feb 3, 2026Transition and Retirement Agreement On February 3, 2026, in connection with James C. Clemmer’s previously announced intention to retire from his position as President and Chief Executive Officer of AngioDynamics, Inc. (“AngioDynamics” or the “Company”) and its subsidiaries (together, the “Company Group”), the Company …Director or officer change · Form 8-K
- Jan 14, 2026J.P. Morgan 44th Annual Healthcare Conference January 14, 2026 Jim Clemmer, President.Regulation FD disclosure · press release
- Jan 6, 2026AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability.Earnings release · press release
- Oct 2, 2025AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Medical Instruments & Supplies
Ranks #20 of 21 by RyuScore